ANI Pharma Q2 revenue $116.5M (+57.8% YoY); raises FY2023 guidance

ANI PHARMACEUTICALS INC

2023-Q2 EPS reported $0.36 revenue$223,333,000

Record Q2 net revenues of $116.5M (up 57.8% YoY); GAAP diluted EPS $0.29 vs $(0.94) loss in Q2 2022.
Adjusted non-GAAP EBITDA $34.1M (up 246% YoY); adjusted diluted EPS $1.28 vs $0.13.
Cortrophin Gel net sales $24.3M (+138.2% YoY); record new patient starts and prescribers.
Raised FY2023 guidance: net revenue $425M-$445M (from $385M-$410M); adj. EBITDA $115M-$125M.
Ended Q2 with $161.7M cash; completed equity offering with $80.6M net proceeds.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ANI PHARMACEUTICALS INC reported Q2 2023 results: revenue $116.5 million, net income $5.8 million, EPS $0.29. Guidance raised.

Period: Q2 2023
Revenue: $116.5 million
Net income: $5.8 million
EPS: $0.29
Guidance: raised
Result: reported results

Exact text from the filing

Pharmaceuticals Reports Record Second Quarter 2023 Financial Results and Raises Full-Year 2023 Guidance Second Quarter 2023 Financial Results -- Record quarterly net revenues of $116.5 million, representing year-over-year growth of 57.8%; net income available to common shareholders of $5.8 million and diluted GAAP income per share of $0.29 -- -- Record quarterly

View on SEC.gov

Browse all earnings releases →

ANI PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001023024-23-000016

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.